| NO |
Title |
Date |
Submission Obligator |
| 10 |
Outcome of Annual Shareholders' Meeting |
2020/03/20 |
HANALL BIOPHARMA CO.,LTD |
| 9 |
Reporting reasons for holding general shareholders' meeting on the most concentrated date |
2020/03/05 |
HANALL BIOPHARMA CO.,LTD |
| 8 |
Decision on Calling Shareholders' Meeting |
2020/03/03 |
HANALL BIOPHARMA CO.,LTD |
| 7 |
Submission of Audit Report |
2020/02/26 |
HANALL BIOPHARMA CO.,LTD |
| 6 |
Implementation and Operation of Compliance Program of the Fair Trade Commission |
2020/02/03 |
HANALL BIOPHARMA CO.,LTD |
| 5 |
[Revised]An Explanation for Rumors or Media Reports |
2020/01/22 |
HANALL BIOPHARMA CO.,LTD |
| 4 |
An Explanation for Rumors or Media Reports |
2020/01/22 |
HANALL BIOPHARMA CO.,LTD |
| 3 |
Designation of overheated short-selling issues (applied by a restriction on short-selling) |
2020/01/21 |
HANALL BIOPHARMA CO.,LTD |
| 2 |
30% or More Changes in Sales or Profits/Losses (15% or More in the case of Large-scale Corporations) |
2020/01/16 |
HANALL BIOPHARMA CO.,LTD |
| 1 |
Interim Report on Business Performance(Fair Disclosure) |
2020/01/16 |
HANALL BIOPHARMA CO.,LTD |